Home VivaMab And ADC Therapeutics Announce Antibody Licensing Deal For Novel ADC Candidate To Target Hematologic Cancers
 

Keywords :   


VivaMab And ADC Therapeutics Announce Antibody Licensing Deal For Novel ADC Candidate To Target Hematologic Cancers

2013-06-24 09:13:00| drugdiscoveryonline News Articles

VivaMab, a therapeutic development division of BioAtla LLC, and ADC Therapeutics Sarl, a portfolio company of Auven Therapeutics and the oncology drug development company specializing in proprietary antibody drug conjugates ('ADCs'), recently announced a licensing deal for a novel antibody against an undisclosed hematological cancer target

Tags: deal target candidate licensing

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
28.11 HEXAGON TR SET UP
28.1121dc hg
28.111EX D
28.11 Bucchus IMP24 FMH-RSM/M
28.11
28.11specialites TA carmina 46-36
28.11HUNTER×HUNTER
28.11
More »